These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19084022)

  • 1. Structure of human MDM4 N-terminal domain bound to a single-domain antibody.
    Yu GW; Vaysburd M; Allen MD; Settanni G; Fersht AR
    J Mol Biol; 2009 Feb; 385(5):1578-89. PubMed ID: 19084022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
    Popowicz GM; Czarna A; Holak TA
    Cell Cycle; 2008 Aug; 7(15):2441-3. PubMed ID: 18677113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain.
    Kussie PH; Gorina S; Marechal V; Elenbaas B; Moreau J; Levine AJ; Pavletich NP
    Science; 1996 Nov; 274(5289):948-53. PubMed ID: 8875929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
    Uhrinova S; Uhrin D; Powers H; Watt K; Zheleva D; Fischer P; McInnes C; Barlow PN
    J Mol Biol; 2005 Jul; 350(3):587-98. PubMed ID: 15953616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
    Shimizu H; Burch LR; Smith AJ; Dornan D; Wallace M; Ball KL; Hupp TR
    J Biol Chem; 2002 Aug; 277(32):28446-58. PubMed ID: 11925449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Progress and Clinical Development of Inhibitors that Block MDM4/p53 Protein-Protein Interactions.
    Zhang S; Lou J; Li Y; Zhou F; Yan Z; Lyu X; Zhao Y
    J Med Chem; 2021 Aug; 64(15):10621-10640. PubMed ID: 34286973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity studies of Mdm2/Mdm4-binding stapled peptides comprising non-natural amino acids.
    Chee SMQ; Wongsantichon J; Siau J; Thean D; Ferrer F; Robinson RC; Lane DP; Brown CJ; Ghadessy FJ
    PLoS One; 2017; 12(12):e0189379. PubMed ID: 29228061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The N-terminal interferon-binding domain (IBiD) homology domain of p300 binds to peptides with homology to the p53 transactivation domain.
    Finlan L; Hupp TR
    J Biol Chem; 2004 Nov; 279(47):49395-405. PubMed ID: 15337767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDM4 binds ligands via a mechanism in which disordered regions become structured.
    Sanchez MC; Renshaw JG; Davies G; Barlow PN; Vogtherr M
    FEBS Lett; 2010 Jul; 584(14):3035-41. PubMed ID: 20515689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2.
    Vogel SM; Bauer MR; Joerger AC; Wilcken R; Brandt T; Veprintsev DB; Rutherford TJ; Fersht AR; Boeckler FM
    Proc Natl Acad Sci U S A; 2012 Oct; 109(42):16906-10. PubMed ID: 23035244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Puzzling over MDM4-p53 network.
    Mancini F; Di Conza G; Monti O; Macchiarulo A; Pellicciari R; Pontecorvi A; Moretti F
    Int J Biochem Cell Biol; 2010 Jul; 42(7):1080-3. PubMed ID: 20417304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adenoviral E1A targets Mdm4 to stabilize tumor suppressor p53.
    Li Z; Day CP; Yang JY; Tsai WB; Lozano G; Shih HM; Hung MC
    Cancer Res; 2004 Dec; 64(24):9080-5. PubMed ID: 15604276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MDM2 gene family.
    Mendoza M; Mandani G; Momand J
    Biomol Concepts; 2014 Mar; 5(1):9-19. PubMed ID: 25372739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structures of the DNA-binding domain tetramer of the p53 tumor suppressor family member p73 bound to different full-site response elements.
    Ethayathulla AS; Nguyen HT; Viadiu H
    J Biol Chem; 2013 Feb; 288(7):4744-54. PubMed ID: 23243311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes.
    Schon O; Friedler A; Freund S; Fersht AR
    J Mol Biol; 2004 Feb; 336(1):197-202. PubMed ID: 14741215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure of the human p53 core domain in the absence of DNA.
    Wang Y; Rosengarth A; Luecke H
    Acta Crystallogr D Biol Crystallogr; 2007 Mar; 63(Pt 3):276-81. PubMed ID: 17327663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
    Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
    Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The evolution of MDM2 family genes.
    Momand J; Villegas A; Belyi VA
    Gene; 2011 Oct; 486(1-2):23-30. PubMed ID: 21762762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.